Trump revives most favored nation plan, but only for Medicaid

5 May 2025

In the USA, the Trump administration is urging congressional Republicans to include a “most favored nation” (MFN) policy in their domestic policy package that would tie Medicaid drug payments to the lowest prices paid in other wealthy countries, a White House official confirmed to Inside Health Policy.

But consumer advocacy group Public Citizen warns the move would generate far less savings than applying the same policy to Medicare.

Under federal law, all US citizens and certain legal immigrants who meet Medicaid's financial and non-financial eligibility criteria are entitled to Medicaid, while Medicare applies to citizens aged over 65 and younger patients with a disability.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical